Clinical Trials Using Nivolumab

Clinical trials are research studies that involve people. The clinical trials on this list are studying Nivolumab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 380

  • A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder

    A study to evaluate Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 with or without BCG in BCG-Unresponsive non-muscle invasive Bladder Cancer
    Location: 10 locations

  • A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

    Patients will receive intra-tumoral (IT) NKTR-262 in 3-week treatment cycles. During the Phase 1 dose escalation portion of the trial, NKTR-262 will be combined with systemic administration of bempegaldesleukin. After determination of the recommended Phase 2 dose (RP2D) of NKTR-262, between 6 and 12 patients may be enrolled at the RP2D to further characterize the safety and tolerability profile of the combination of NKTR 262 plus bempegaldesleukin (doublet) or NKTR 262 plus bempegaldesleukin in combination with nivolumab (triplet) in Cohorts A and B, respectively. In the Phase 2 dose expansion portion, patients will be treated with doublet or triplet in the relapsed / refractory setting and earlier lines of therapy.
    Location: 14 locations

  • A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

    This dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IPI-549 monotherapy and IPI-549 in combination with nivolumab in subjects with advanced solid tumors.
    Location: 9 locations

  • Cisplatin, Romidepsin and Nivolumab in Treating Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer

    This phase I / II trial studies the side effects and best dose of romidepsin when given together with cisplatin and nivolumab, to see how well they work in treating patients with triple negative breast cancer that has come back at or near the same place as the original (primary) tumor, usually after a period of time during which the cancer could not be detected or spread to other parts of the body. Romidepsin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Romidepsin may also help cisplatin work better. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving romidepsin together with cisplatin and nivolumab may be a better treatment for tripe negative breast cancer.
    Location: 8 locations

  • Azacitidine, Entinostat, and Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer

    This phase II trial studies how well azacitidine, entinostat, and nivolumab or nivolumab alone work in treating patients with non-small cell lung cancer that has come back and has spread to other places in the body. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may kill tumor cells that are left after chemotherapy. It is not yet known if azacitidine and entinostat followed by nivolumab or nivolumab alone is more effective in treating non-small cell lung cancer.
    Location: 8 locations

  • Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Aggressive Pituitary Tumors

    This phase II trial studies how well nivolumab and ipilimumab work in treating pituitary tumors that form, grow, or spread quickly (aggressive). Nivolumab blocks the protein PD-1, which can act as a brake on the immune system. Blocking PD-1 releases the brakes, so the immune system can recognize tumor cells and kill them. Ipilimumab acts against a protein called CTLA-4, which can slow down or turn off the immune system. Blocking CTLA-4 allows the body to have an immune reaction that helps destroy tumor cells. The purpose of this study is to find out whether the study drugs, nivolumab and ipilimumab, are an effective treatment for people with pituitary tumors.
    Location: 7 locations

  • Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. Approximately 676 eligible subjects with intermediate- or poor-risk advanced or metastatic RCC by IMDC criteria will be randomized in a 1:1 ratio (~338 per treatment arm) at approximately 150 sites.
    Location: 8 locations

  • Brentuximab Vedotin and Nivolumab in Treating Patients with Early Stage Classic Hodgkin Lymphoma

    This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 17 locations

  • A Study of a Personalized Neoantigen Cancer Vaccine

    The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, gastroesophageal adenocarcinoma, and metastatic urothelial cancer.
    Location: 8 locations

  • Nivolumab and Cabozantinib S-malate in Treating Patients with Advanced or Metastatic Kidney Cancer

    This phase II trial studies how well nivolumab and cabozantinib s-malate work in treating patients with kidney cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving nivolumab and cabozantinib s-malate may work better in treating patients with advanced or metastatic kidney cancer.
    Location: 7 locations

  • A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma

    The primary purpose of this study is to demonstrate that the NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab is safe for the treatment of patients with advanced or metastatic melanoma. The study will also investigate an alternative schedule for the administration of the NEO-PV-01 vaccine. Study interventions will be assessed by both clinical and immune responses to treatment.
    Location: 7 locations

  • GMCI, Nivolumab, Radiation Therapy, and Temozolomide in Treating Patients with Newly Diagnosed High-Grade Gliomas

    This phase I trial studies the side effects and best dose of aglatimagene besadenovec and valacyclovir (gene mediated cytotoxic immunotherapy [GMCI]), nivolumab, radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade gliomas. Aglatimagene besadenovec and valacyclovir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving GMCI, nivolumab, radiation therapy, and temozolomide may work better in treating patients with high-grade gliomas.
    Location: 7 locations

  • An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

    The purpose of this study is to determine whether BMS-986249 both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors
    Location: 7 locations

  • Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors

    This phase II trial studies how well nivolumab and ipilimumab work in treating patients with rare genitourinary tumors that have spread to other anatomic sites or is no longer responding to treatment. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • Nivolumab in Treating Patients with Metastatic or Recurrent Uterine Cancer

    This phase II trial studies how well nivolumab works in treating patients with uterine cancer that has spread to other places in the body (metastatic) or come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • Nivolumab and Ipilimumab in Treating Patients with Adenoid Cystic Cancer or Recurrent or Metastatic Salivary Gland Cancer

    This phase II trial studies how well nivolumab and ipilimumab work in treating patients with adenoid cystic cancer or salivary gland cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 7 locations

  • CD40 Agonistic Antibody APX005M in Combination With Nivolumab

    This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.
    Location: 7 locations

  • Nivolumab and Combination Chemotherapy in Treating Patients with Untreated Stage III-IV Classical Hodgkin Lymphoma

    This phase I trial studies the best dose and side effects of nivolumab and combination chemotherapy in treating patients with untreated stage III-IV classical Hodgkin Lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in combination chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine, and dacarbazine (ABVD) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab and more than one drug (combination chemotherapy) may kill more tumor cells and work better at treating Hodgkin lymphoma.
    Location: 10 locations

  • An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

    A study to evaluate the safety of Nivolumab given in combination with Ipilimumab in patients with advanced cancers. The initial group will enroll patients with newly diagnosed Stage 4 or non-small cell lung cancer that has come back.
    Location: 7 locations

  • A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors

    Multicenter, open-label, phase 1a / 1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumors.
    Location: 9 locations

  • A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing Malignant Pleural Mesothelioma

    This phase I trial studies the side effects of a vaccine, galinpepimut-S, and nivolumab in treating patients with WT1 positive malignant pleural mesothelioma. Vaccines, such as galinpepimut-S, are made from Wilms Tumor Protein 1 (WT1) peptide and may help the body build an effective immune response to kill tumor cells that express WT1. Galinpepimut-S is mixed with a substance called montanide, which helps to boost the immune reaction to galinpepimut-S. The mixture of the galinpepimut-S and montanide make up the actual final vaccine that is then given to patients. Immunotherapy with monoclonal antibodies, such as nivolumab, may remove signals that block the immune system’s activity, indirectly strengthening the immune system to help fight the cancer. It has been shown that cancer vaccines can sometimes increase these signals that actually block the immune system’s anti-cancer activity. Using a cancer vaccine (galinpepimut-S) directed to mesothelioma cells with a drug that can unblock these negative signals (nivolumab) may help treat malignant pleural mesothelioma.
    Location: 6 locations

  • A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

    The main purpose of this study is to compare the overall response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy (sunitinib or cabozantinib) in IMDC intermediate- or poor-risk patients and IMDC all-risk patients with previously untreated advanced renal cell carcinoma (RCC).
    Location: 7 locations

  • Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery

    This phase II / III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with antibodies, such as nivolumab and ipilimumab, may remove the brake on the body’s immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy and radiation therapy may reduce the tumor size and the amount of normal tissue that needs to be removed during surgery. A combined treatment with nivolumab and ipilimumab, chemotherapy, and radiation therapy might be more effective in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery.
    Location: 6 locations

  • Combination Immunotherapy (Nivolumab and Ipilimumab) in Treating Patients with CDK12 Loss and Metastatic Prostate Cancer or Other Metastatic Cancers, IMPACT Study

    This phase II trial studies how well nivolumab and ipilimumab work in treating patients with a type of genetic mutation called CDK12 loss and prostate cancer or other cancers that have spread to other places in the body. Cancer is caused by changes (mutations) to genes that control the way our cells function; especially how they repair mistakes that crop up during regular growth and turnover. The normal proof-reading system in the cells tries to fix the DNA mistakes. CDK12 is part of the body's proof-reading system that fixes mistakes in genetic information. Tumor cells that carry CDK12 loss cannot fix these mistakes well. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of nivolumab plus ipilimumab for metastatic prostate cancer and other cancer types that have mutations of the CDK12 gene making this gene stop working.
    Location: 6 locations

  • Phase Ib Feasibility Trial of Neoadjuvant Nivolumab / Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

    Patients with muscle-invasive bladder cancer (MIBC) who can not receive cisplatin or refuse cisplatin therapy will receive nivolumab or nivolumab / lirilumab before a planned surgical procedure called a radical cystectomy (RC) to remove the bladder. Nivolumab works by attaching to and blocking a molecule called Programmed Death-1 (PD-1). Lirilumab attaches to and blocks a group of molecules called Killer Cell Immunoglobulin-Like Receptor (KIR). PD-1 and KIR are proteins present mainly on immune system cells, and each controls part of the immune system by shutting it down. It is hoped that by binding to and inactivating these proteins, these drugs can enhance the body's ability to detect, attack and destroy cancer cells. The purpose of this research study is to see whether nivolumab alone or combination of nivolumab and lirilumab given before surgery is effective in treating people who have bladder cancer, and to examine the side effects, good and bad, associated with nivolumab and lirilumab.
    Location: 7 locations